Digestive Physiology, Department of Digestive Diseases, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
Eur J Gastroenterol Hepatol. 2010 May;22(5):532-40. doi: 10.1097/MEG.0b013e3283343f58.
Recently, noninvasive methods for the diagnosis of liver cirrhosis have been extensively developed. We assessed the accuracy of liver stiffness measurement, aspartate aminotransferase-to-platelet ratio index (APRI) score, 13C-aminopyrine breath test, and indocyanine green plasma clearance for the diagnosis of cirrhosis in patients with chronic liver disease and for the prediction of severe complications in cirrhotic patients.
A total of 296 consecutive patients with chronic liver diseases of various causes were studied. Diagnostic accuracy was assessed by receiver operating characteristic curve analysis.
Areas under the receiver operating characteristic curve for the diagnosis of cirrhosis were (95% confidence interval) 0.93 (0.90-0.96) for liver stiffness measurement, 0.82 (0.77-0.87) for 13C-aminopyrine breath test, and 0.81 (0.76-0.86) for APRI score. Using cutoff values of 14.1 kPa for liver stiffness, 4.15% dose/h for 13C-aminopyrine breath test, and 1 for APRI score, the positive predictive value was approximately 90% for the diagnosis of cirrhosis. Using cutoff values of 65.2 kPa for liver stiffness, 1.17% dose/h for 13C-aminopyrine breath test, 2.82 for APRI score, and 51.1% for indocyanine green plasma clearance, the positive predictive value was approximately 80% for the occurrence of severe complications among cirrhotic patients.
Liver stiffness measurement, 13C-aminopyrine breath test, indocyanine green plasma clearance, and APRI score are reliable noninvasive methods for the diagnosis of cirrhosis in patients with chronic liver diseases of various causes, and are also prognostic indicators for the occurrence of severe complications in cirrhotic patients.
最近,非侵入性的方法来诊断肝硬化已经得到了广泛的发展。我们评估了肝硬度测量、天冬氨酸氨基转移酶-血小板比值指数(APRI)评分、13C-氨基比林呼气试验和吲哚菁绿血浆清除率在诊断慢性肝病患者肝硬化和预测肝硬化患者严重并发症中的准确性。
共研究了 296 例不同病因的慢性肝病患者。通过接收者操作特征曲线分析评估诊断准确性。
肝硬度测量、13C-氨基比林呼气试验和 APRI 评分诊断肝硬化的受试者工作特征曲线下面积分别为(95%置信区间)0.93(0.90-0.96)、0.82(0.77-0.87)和 0.81(0.76-0.86)。使用肝硬度 14.1kPa 的截断值、13C-氨基比林呼气试验 4.15%剂量/h 和 APRI 评分 1,诊断肝硬化的阳性预测值约为 90%。使用肝硬度 65.2kPa 的截断值、13C-氨基比林呼气试验 1.17%剂量/h、APRI 评分 2.82 和吲哚菁绿血浆清除率 51.1%,肝硬化患者严重并发症发生的阳性预测值约为 80%。
肝硬度测量、13C-氨基比林呼气试验、吲哚菁绿血浆清除率和 APRI 评分是诊断各种病因慢性肝病患者肝硬化的可靠非侵入性方法,也是预测肝硬化患者严重并发症发生的预后指标。